The biosimilars firm Alvotech (Nasdaq:ALVO) has announced that its CEO, Mark Levick, will retire. As of January 1, the company will install Robert Wessman, executive chairman and founder, as its top exec.
Reykjavik, Iceland–based Alvotech also announced that it had retained Hafrun Fridriksdottir as its chief operating officer. Fridriksdottir was formerly the executive vice president and head of global R&D at Teva (NYSE:TEVA).
Wessman will retain his role as executive chairman of Alvotech’s board.
At Teva, Fridriksdottir managed a pipeline of more than 1,000 generic drugs and dozens of biosimilars. She led 3,500 international employees in that role.
She has also held roles at Gacell Laboratories, Omega Pharma, the generics firm Actavis (now owned by Teva) and Allergan (now part of AbbVie).
Wessman founded Alvotech in 2013 and began his stint as board chairman in …